Jump Financial LLC Buys Shares of 4,427 Jazz Pharmaceuticals PLC $JAZZ

Key Points

• Jump Financial LLC acquired a new position in Jazz Pharmaceuticals PLC by purchasing 4,427 shares valued at approximately $550,000 in the first quarter of 2023.
• CEO Bruce C. Cozadd sold 1,000 shares of Jazz Pharmaceuticals at an average price of $107.63, resulting in a 0.23% decrease in his ownership of the stock.
• Jazz Pharmaceuticals reported a loss of ($8.25) EPS for the quarter, missing analysts' estimates, while setting FY 2025 guidance at 4.800-5.600 EPS.

Jump Financial LLC purchased a new stake in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report) in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 4,427 shares of the specialty pharmaceutical company's stock, valued at approximately $550,000.

Other institutional investors also recently bought and sold shares of the company. Hurley Capital LLC purchased a new stake in shares of Jazz Pharmaceuticals in the first quarter valued at approximately $25,000. Elequin Capital LP increased its position in shares of Jazz Pharmaceuticals by 677.8% in the fourth quarter. Elequin Capital LP now owns 210 shares of the specialty pharmaceutical company's stock valued at $26,000 after buying an additional 183 shares in the last quarter. Parallel Advisors LLC increased its position in shares of Jazz Pharmaceuticals by 85.6% in the first quarter. Parallel Advisors LLC now owns 258 shares of the specialty pharmaceutical company's stock valued at $32,000 after buying an additional 119 shares in the last quarter. Picton Mahoney Asset Management increased its position in shares of Jazz Pharmaceuticals by 2,445.5% in the first quarter. Picton Mahoney Asset Management now owns 280 shares of the specialty pharmaceutical company's stock valued at $34,000 after buying an additional 269 shares in the last quarter. Finally, Spire Wealth Management increased its position in shares of Jazz Pharmaceuticals by 137.6% in the first quarter. Spire Wealth Management now owns 278 shares of the specialty pharmaceutical company's stock valued at $35,000 after buying an additional 161 shares in the last quarter. 89.14% of the stock is currently owned by hedge funds and other institutional investors.

Jazz Pharmaceuticals Price Performance

Shares of JAZZ traded down $3.62 during trading hours on Thursday, hitting $128.10. 335,718 shares of the stock were exchanged, compared to its average volume of 944,548. The company has a debt-to-equity ratio of 1.17, a quick ratio of 1.37 and a current ratio of 1.62. The stock's 50-day moving average price is $115.82 and its two-hundred day moving average price is $117.12. The company has a market cap of $7.77 billion, a price-to-earnings ratio of -19.08, a price-to-earnings-growth ratio of 8.04 and a beta of 0.24. Jazz Pharmaceuticals PLC has a 12-month low of $95.49 and a 12-month high of $148.06.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last issued its earnings results on Tuesday, August 5th. The specialty pharmaceutical company reported ($8.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($5.61) by ($2.64). The company had revenue of $1.05 billion during the quarter, compared to analysts' expectations of $1.05 billion. Jazz Pharmaceuticals had a negative net margin of 9.91% and a positive return on equity of 5.02%. The firm's quarterly revenue was up 2.1% compared to the same quarter last year. During the same quarter in the previous year, the company earned $5.30 earnings per share. Jazz Pharmaceuticals has set its FY 2025 guidance at 4.800-5.600 EPS. Research analysts expect that Jazz Pharmaceuticals PLC will post 16.96 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on the company. Zacks Research upgraded Jazz Pharmaceuticals from a "strong sell" rating to a "hold" rating in a research report on Friday, August 15th. Morgan Stanley boosted their price objective on Jazz Pharmaceuticals from $162.00 to $163.00 and gave the company an "overweight" rating in a research report on Thursday, August 28th. Royal Bank Of Canada boosted their price target on Jazz Pharmaceuticals from $145.00 to $151.00 and gave the stock an "outperform" rating in a research report on Thursday, August 28th. The Goldman Sachs Group boosted their price target on Jazz Pharmaceuticals from $162.00 to $185.00 and gave the stock a "buy" rating in a research report on Friday, August 29th. Finally, Needham & Company LLC reiterated a "buy" rating and set a $202.00 price target on shares of Jazz Pharmaceuticals in a research report on Thursday, August 28th. Fourteen analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $178.67.

Insider Transactions at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 1,000 shares of the company's stock in a transaction on Tuesday, July 1st. The stock was sold at an average price of $107.63, for a total value of $107,630.00. Following the completion of the sale, the chief executive officer directly owned 436,973 shares in the company, valued at $47,031,403.99. This represents a 0.23% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 4.30% of the stock is currently owned by insiders.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.